MUNASET: Month 6 meeting took place in Zweibruecken 29th February 2024

The objective of the Graphene Flagship's MUNASET project is to develop a rapid, highly sensitive and easy-to-use graphene-based biosensor platform to monitor the therapy response of patients suffering from major depressive disorder (MDD). This platform  allows faster and more precise identification of the optimal treatment strategy and therefore improves the expected therapy outcomes while also reducing the  hospitalization time. MUNASET will help secure Europe’s industrial leadership over the entire value chain of novel graphene-based bio-analytical tools. The project, funded by the European Commission’s Horizon Europe programme, is part of the Graphene Flagship initiative which works to advance technologies that rely on graphene and other 2D materials. 

The MUNASET consortium received over 4 million euros funding to cover the project activities for 4 years and is under the leadership of Professor Alexey Tarasov (University of Applied Sciences Kaiserslautern). It is composed of six partners across four European countries: Germany, Finland, Belgium and Spain. The consortium members include: Graphenea Semiconductor SL, Johannes Gutenberg University Mainz, VTT Technical Research Centre of Finland Ltd, Mainz University Medical Center and ProActive ltd. The MUNASET project is a new member of the Graphene Flagship Initiative. A meeting after the sixth month of the project took place in Zweibruecken  on 29 February. 

The meeting after the sixth month of the project allowed all partners to present the work carried out so far, it permitted the partners to analyse the current issues and to fine tune the next actions. So far MUNASET has achieved all of its set objectives for this period.